Showing Results for
- Academic Journals (34)
Search Results
- 34
Academic Journals
- 34
- Search Terms:
- 1From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedThe therapeutic potential of using small interfering RNA (siRNA) to inhibit the expression of specific genes is well recognized. However, successfully translating this technology into the clinic has faced several...
- 2From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedGlaxoSmithKline (GSK) has established a collaboration with Regulus Therapeutics to develop and commercialize therapeutics targeting microRNA-122 for hepatitis C virus (HCV) infection. Although a clinical development...
- 3From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedMcNeish, J. et al. J. Biol. Chem. 8 Mar 2010 (doi/10.1074/jbc.M109.098814) This paper reports one of the first stem cell-based screens to identify biologically active lead molecules. A screen of more than 2.4 million...
- 4From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedThe Critical Path Institute, The Global Alliance for TB drug development (TB Alliance) and the Bill and Melinda Gates Foundation have launched an initiative to accelerate the development of combination therapies for the...
- 5From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedAn important outcome of the focus on the human genome in the past decade has been the understanding that cancer is largely a disease of aberrant cell signalling. The development of drugs that target the results of...
- 6From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedA US district court judge has ruled that human BRCA1 (breast cancer 1, early onset) and BRCA2 genes are not patentable because they are products of nature. Although the immediate impact of this decision is likely to be...
- 7From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedSeven-transmembrane receptors (7TMRs; also known as G protein-coupled receptors) are the largest class of receptors in the human genome and are common targets for therapeutics. Originally identified as mediators of 7TMR...
- 8From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedPotential strategies aimed at inhibiting the progression of Alzheimer's disease include targeting the production and clearance of the amyloid-[beta] (A[beta]) peptide, which is thought to be important in the...
- 9From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedThe effects of a tumour's microenvironment can adversely affect the activity of chemotherapeutic agents and lead to what is referred to as stroma-induced chemoresistance. In Nature Medicine, Mitsiades and colleagues...
- 10From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedIn February 2010, aztreonam for inhalation solution (Cayston; Gilead)--an inhalable formulation of the monobactam antibiotic aztreonam and lysine--was approved by the US FDA to improve respiratory symptoms in patients...
- 11From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedElevation of cytosolic [Ca.sup.2+] levels through the activation of store-operated [Ca.sup.2+] release-activated [Ca.sup.2+] (CRAC) channels is involved in mediating a disparate array of cellular responses. These...
- 12From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedOn 17 March 2010, the Biomarkers Consortium launched a pioneering adaptive clinical trial of several investigational drugs to treat breast cancer, called I-SPY 2 (BOX 1). This represents the first time that the...
- 13From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedNature Reviews Drug Discovery 8, 129-138 (2009) | doi: 10.1038/nrd2742 On page 136, in the glossary term and in the main text, age-related macular degeneration (AMD) has been incorrectly attributed to "excessive...
- 14From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedNovartis has reported that LCZ696--a first-in-class dual-acting angiotensin II (AT2) receptor and neprilysin inhibitor--demonstrated superior blood-pressure-lowering efficacy in a Phase II trial of patients with...
- 15From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedTraditionally, signalling through seven-transmembrane receptors (7TMRs)--which are one of the largest classes of drug targets--was thought to be mediated solely via G proteins. Recently, however, it has been...
- 16From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedA hearing before the full US Court of Appeals for the Federal Circuit (CAFC) examining the 'written description' requirement of US patent law has seen Ariad's patent directed towards the nuclear factor-[kappa]B...
- 17From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedHigh-throughput screening technologies are widely used in the early stages of drug discovery to rapidly evaluate the properties of thousands of compounds. However, they generally rely on testing compound libraries on...
- 18From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedThalidomide, a sedative that caused severe birth defects 50 years ago when it was prescribed to pregnant women, has enjoyed revived interest owing to its potency as an anti-angiogenic and anti-inflammatory agent. It is...
- 19From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedExecutive dean for research, Harvard Medical School, Boston, Massachusetts, USA. Prior to his appointment at Harvard Medical School (HMS), William Chin, M.D., was at Eli Lilly and Company (Lilly) for 11 years, most...
- 20From: Nature Reviews Drug Discovery. (Vol. 9, Issue 5) Peer-ReviewedWang, M.-Y. et al. Proc. Natl Acad. Sci. USA 107, 4813-4819 (2010) In type 1 diabetes, injected insulin does not replicate the metabolic homeostasis produced by endogenous insulin. Wang and colleagues showed that in...